A detailed history of Dynamic Technology Lab Private LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 22,791 shares of EXEL stock, worth $830,276. This represents 0.06% of its overall portfolio holdings.

Number of Shares
22,791
Holding current value
$830,276
% of portfolio
0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $500,490 - $629,031
22,791 New
22,791 $591,000
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $543,392 - $612,474
29,906 New
29,906 $572,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $648,681 - $921,309
41,370 Added 128.32%
73,610 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $648,681 - $921,309
41,370 Added 128.32%
73,610 $1.15 Million
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $562,265 - $746,678
32,240 New
32,240 $671,000
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $231,846 - $308,629
-13,614 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $215,645 - $297,874
13,614 New
13,614 $249,000
Q3 2021

Nov 15, 2021

SELL
$16.3 - $21.14 $198,191 - $257,041
-12,159 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$17.95 - $25.56 $261,639 - $372,562
-14,576 Reduced 54.52%
12,159 $222,000
Q1 2021

May 14, 2021

BUY
$20.53 - $25.22 $548,869 - $674,256
26,735 New
26,735 $604,000
Q4 2019

Feb 14, 2020

SELL
$15.15 - $18.89 $278,426 - $347,160
-18,378 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $324,923 - $416,261
18,378 New
18,378 $325,000
Q1 2019

May 13, 2019

SELL
$19.6 - $24.76 $378,809 - $478,536
-19,327 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $93,174 - $148,806
6,826 Added 54.6%
19,327 $380,000
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $198,390 - $280,022
12,501 New
12,501 $222,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.